This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

BEN-ZION GARTY, MD; RIVKA KAULI, MD; ELLA LIVNI, PHD; ZVI LARON, MD; MENACHEM NITZAN, MD
Department of Pediatrics Beilinson Medical Center Petah Tiqva 49100, Israel

Am J Dis Child. 1991;145(9):970-971.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Sir.—Ketoconazole is an imidazole-derivative, broad-spectrum antimycotic agent, with relatively limited toxicity compared with other antifungal medications. However, gastrointestinal disturbances, hepatotoxicity, impaired adrenal steroidogenesis, gynecomastia, and immune hemolytic anemia have been reported in association with ketoconazole treatment.^1,2 We noticed myopathy with a significant increase of serum creatine phosphokinase during ketoconazole treatment, indicating a possible drug-induced myositis. To our knowledge, there has been no fully documented report of myopathy associated with the use of this drug, although myalgia has been reported in two patients³ and muscular weakness in one patient.⁴

Patient Report.—A 17-year-old boy afflicted with autoimmune polyglandular syndrome type I presented with hypoparathyroidism, Addison's disease, alopecia universalis, and mucocutaneous candidiasis was treated with ketoconazole (200 mg/d) because of worsening oral candidiasis. Within a week, doctors noticed clinical improvement of the oral lesions, but concomitantly, the patient developed significant weakness and diffuse myalgia, particularly of the shoulder . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?